Pasithea Therapeutics Corp (KTTA)
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company listed on NASDAQ under the ticker KTTA. The company focuses on discovering and developing therapies for central nervous system disorders, RASopathies, and cancer. Its lead candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor being developed for a range of RASopathies, including neurofibromatosis type 1, as well as MAPK pathway-driven tumors such as BRAFv600 and BRAF fusion tumors. PAS-004 is also being studied for ETS2-driven conditions, including inflammatory bowel disease, primary sclerosing cholangitis, and ankylosing spondylitis. Pasithea’s lead development candidate, PAS-003, is targeted at amyotrophic lateral sclerosis, and the company also plans to advance PAS-001 for schizophrenia. Incorporated in 2020, Pasithea Therapeutics is headquartered in Miami Beach, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KTTA
|
$0.62
|
36.7% Upside
|
Undervalued
|
$3
|
563.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-0.8x
|
0.3x
|
—
|
15.812 M
|
-35.197 M
|
0.0%
|
49.8%
|
40.2
|
—
|
85.9%
|
